Rep. Robert Bresnahan, Jr. Sells Off Shares of Biogen Inc. (NASDAQ:BIIB)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Biogen Inc. NASDAQ: BIIB. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Biogen stock on April 8th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/17/2025.
• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Texas Instruments NASDAQ: TXN on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/10/2025.
• Sold $1,001 - $15,000 in shares of DexCom NASDAQ: DXCM on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.

Biogen Stock Down 0.5%

Biogen stock traded down $0.65 during trading hours on Thursday, hitting $119.72. The company had a trading volume of 60,882 shares, compared to its average volume of 1,371,865. The firm has a market capitalization of $17.54 billion, a P/E ratio of 10.70, a price-to-earnings-growth ratio of 1.51 and a beta of 0.12. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $238.00. The firm's fifty day moving average is $126.86 and its 200-day moving average is $143.40.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biotechnology company reported $3.02 EPS for the quarter, missing the consensus estimate of $3.26 by ($0.24). Biogen had a return on equity of 14.98% and a net margin of 16.87%. The business had revenue of $2.43 billion for the quarter, compared to analyst estimates of $2.25 billion. During the same quarter in the prior year, the firm earned $3.67 EPS. The firm's quarterly revenue was up 6.2% compared to the same quarter last year. On average, research analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current year.

Analysts Set New Price Targets

BIIB has been the topic of several research reports. Royal Bank of Canada lowered their price objective on shares of Biogen from $217.00 to $205.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Hsbc Global Res downgraded shares of Biogen from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 28th. Sanford C. Bernstein started coverage on shares of Biogen in a report on Tuesday, February 11th. They issued a "market perform" rating and a $160.00 target price on the stock. Canaccord Genuity Group lowered their price target on shares of Biogen from $265.00 to $220.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Finally, Robert W. Baird cut their price objective on Biogen from $300.00 to $255.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Twenty equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $191.30.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BIIB. Signaturefd LLC grew its holdings in Biogen by 3.5% in the 4th quarter. Signaturefd LLC now owns 2,092 shares of the biotechnology company's stock worth $320,000 after buying an additional 71 shares in the last quarter. Quent Capital LLC lifted its holdings in Biogen by 31.9% in the 4th quarter. Quent Capital LLC now owns 298 shares of the biotechnology company's stock worth $46,000 after purchasing an additional 72 shares during the last quarter. Principal Securities Inc. grew its holdings in Biogen by 30.1% in the 4th quarter. Principal Securities Inc. now owns 337 shares of the biotechnology company's stock valued at $52,000 after buying an additional 78 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Biogen by 1.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,018 shares of the biotechnology company's stock valued at $767,000 after purchasing an additional 79 shares during the period. Finally, Israel Discount Bank of New York increased its holdings in shares of Biogen by 6.2% in the fourth quarter. Israel Discount Bank of New York now owns 1,405 shares of the biotechnology company's stock valued at $215,000 after purchasing an additional 82 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company's stock.

Insider Transactions at Biogen

In related news, Director Stephen A. Sherwin sold 8,760 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the transaction, the director now directly owns 11,318 shares of the company's stock, valued at approximately $1,697,926.36. This trade represents a 43.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.